Proteostasis Therapeutics Inc (PTI) Insider Sells $323,500.00 in Stock

Proteostasis Therapeutics Inc (NASDAQ:PTI) insider Fmr Llc sold 25,000 shares of the stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $12.94, for a total value of $323,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Fmr Llc also recently made the following trade(s):

  • On Friday, March 10th, Fmr Llc sold 25,000 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $12.04, for a total value of $301,000.00.
  • On Thursday, March 9th, Fmr Llc sold 29,300 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $12.08, for a total value of $353,944.00.
  • On Tuesday, March 7th, Fmr Llc sold 60,000 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $13.01, for a total value of $780,600.00.
  • On Friday, March 3rd, Fmr Llc sold 45,000 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $13.91, for a total value of $625,950.00.
  • On Wednesday, March 1st, Fmr Llc sold 45,000 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $14.62, for a total value of $657,900.00.
  • On Monday, February 27th, Fmr Llc sold 28,000 shares of Proteostasis Therapeutics stock. The shares were sold at an average price of $14.60, for a total value of $408,800.00.

Shares of Proteostasis Therapeutics Inc (NASDAQ:PTI) opened at 12.41 on Monday. Proteostasis Therapeutics Inc has a 52-week low of $6.61 and a 52-week high of $20.63. The company’s market capitalization is $309.75 million. The stock has a 50 day moving average price of $14.10 and a 200 day moving average price of $12.81.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Your IP Address:

A number of large investors have recently made changes to their positions in PTI. Marshall Wace LLP raised its stake in shares of Proteostasis Therapeutics by 32.2% in the fourth quarter. Marshall Wace LLP now owns 442,836 shares of the company’s stock worth $5,429,000 after buying an additional 107,866 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Proteostasis Therapeutics during the fourth quarter worth about $240,000. Hillhouse Capital Management Ltd. purchased a new stake in shares of Proteostasis Therapeutics during the third quarter worth about $11,907,000. Rock Springs Capital Management LP raised its stake in shares of Proteostasis Therapeutics by 8.4% in the third quarter. Rock Springs Capital Management LP now owns 450,000 shares of the company’s stock worth $7,016,000 after buying an additional 35,000 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Proteostasis Therapeutics during the third quarter worth about $395,000. 67.71% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 15th. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, January 24th.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

5 Day Chart for NASDAQ:PTI

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/proteostasis-therapeutics-inc-pti-insider-sells-323500-00-in-stock/1708636.html

Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *